Promising Phase III data for a new passive vaccine against RSV
May 10, 2021Infection by Respiratory Syncytial Virus (RSV) is the leading cause of hospitalization in infants. The currently available preventive treatment is a monthly injection with an anti-RSV antibody, which is only given to high-risk infants and only temporarily provides protection due to a limited half-life. Now, a new antibody against RSV, which was developed by scientists of Amsterdam UMC
spin-off AIMM Therapeutics, has come one step closer to market authorization, showing positive results in a Phase III clinical trial performed by pharma companies Astra Zeneca and Sanofi. This antibody, being more stable than the existing antibody, will only need to be administered once per RSV-season and should become available to all infants.
For more information click here.
Photo credit: Respiratory syncytial virus (RSV) infection – Case 288 by Yale Rosen. Photo is cropped.
More news
Sign up for Amsterdam Science & Innovation Award 2023
Do you have an innovative idea that could positively impact tomorrow’s world?
Submit your idea and compete to win € 10,000!
Max Nijman (founder Flame Away) one of the 50 FD Talents
Only available in Dutch. Max Nijman, oprichter van VU startup Flame Away, is verkozen als een van de 50 talenten die verschijnen in het Financieel Dagblad 50 onder de 35. Dit is een lijst waarin gekeken wordt naar jonge talenten die de wereld een stukje beter maken. Max startte drie jaar geleden met een studieproject […]
News
Kick-off Biotech Booster programme in Amsterdam: Thematic Cluster 4 ‘Diagnostics/Services’
We’re off! As part of the Biotech Booster programme, IXA is setting up the Thematic Cluster 4 ‘Diagnostics/Services’ in Amsterdam.
News